HK1258761A1 - 乙肝核心蛋白調節劑 - Google Patents
乙肝核心蛋白調節劑Info
- Publication number
- HK1258761A1 HK1258761A1 HK19101079.1A HK19101079A HK1258761A1 HK 1258761 A1 HK1258761 A1 HK 1258761A1 HK 19101079 A HK19101079 A HK 19101079A HK 1258761 A1 HK1258761 A1 HK 1258761A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hepatitis
- core protein
- protein modulators
- modulators
- core
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562218815P | 2015-09-15 | 2015-09-15 | |
PCT/US2016/051934 WO2017048950A1 (en) | 2015-09-15 | 2016-09-15 | Hepatitis b core protein modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1258761A1 true HK1258761A1 (zh) | 2019-11-22 |
Family
ID=58289869
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK19101079.1A HK1258761A1 (zh) | 2015-09-15 | 2019-01-22 | 乙肝核心蛋白調節劑 |
HK19101078.2A HK1258697A1 (zh) | 2015-09-15 | 2019-01-22 | 乙肝核心蛋白調節劑 |
HK19101106.8A HK1259141A1 (zh) | 2015-09-15 | 2019-01-22 | 乙肝核心蛋白調節劑 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK19101078.2A HK1258697A1 (zh) | 2015-09-15 | 2019-01-22 | 乙肝核心蛋白調節劑 |
HK19101106.8A HK1259141A1 (zh) | 2015-09-15 | 2019-01-22 | 乙肝核心蛋白調節劑 |
Country Status (28)
Country | Link |
---|---|
US (6) | US10377748B2 (zh) |
EP (4) | EP3349761B1 (zh) |
JP (4) | JP7023838B2 (zh) |
KR (3) | KR20180053363A (zh) |
CN (4) | CN108348529A (zh) |
AR (3) | AR106040A1 (zh) |
AU (4) | AU2016323305A1 (zh) |
CA (3) | CA2998793A1 (zh) |
CL (2) | CL2018000684A1 (zh) |
CY (1) | CY1123570T1 (zh) |
DK (1) | DK3349580T3 (zh) |
DO (1) | DOP2018000074A (zh) |
EA (3) | EA201890736A1 (zh) |
ES (2) | ES2905950T3 (zh) |
HK (3) | HK1258761A1 (zh) |
HR (1) | HRP20201812T1 (zh) |
HU (1) | HUE051872T2 (zh) |
IL (3) | IL258099A (zh) |
LT (1) | LT3349580T (zh) |
MX (4) | MX2018003207A (zh) |
PH (3) | PH12018500572A1 (zh) |
PT (1) | PT3349580T (zh) |
RS (1) | RS61064B1 (zh) |
SG (1) | SG10202011103UA (zh) |
SI (1) | SI3349580T1 (zh) |
TW (4) | TWI786639B (zh) |
WO (3) | WO2017048950A1 (zh) |
ZA (1) | ZA201802456B (zh) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2942533C (en) | 2014-03-13 | 2020-12-08 | Indiana University Research And Technology Corporation | Hepatitis b core protein allosteric modulators |
TWI786639B (zh) * | 2015-09-15 | 2022-12-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
CN109937201A (zh) * | 2016-09-15 | 2019-06-25 | 组装生物科学股份有限公司 | 乙型肝炎核心蛋白调节剂 |
BR112019007450A2 (pt) | 2016-10-14 | 2020-07-07 | Precision Biosciences, Inc. | meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b |
US10821103B2 (en) | 2016-11-07 | 2020-11-03 | Arbutus Biopharma Corporation | Substituted pyridinone-containing trycyclic compounds, and methods using same |
SG11201907725SA (en) * | 2017-02-23 | 2019-09-27 | Fujian Cosunter Pharmaceutical Co Ltd | Tri-cycle compound and applications thereof |
WO2018160878A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
EP3596070A1 (en) * | 2017-03-13 | 2020-01-22 | Assembly Biosciences, Inc. | Process for making hepatitis b core protein modulators |
AU2018238138A1 (en) | 2017-03-21 | 2019-10-17 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
AR115131A1 (es) | 2017-11-02 | 2020-12-02 | Aicuris Gmbh & Co Kg | Altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb) |
CU20200037A7 (es) | 2017-11-02 | 2021-03-11 | Aicuris Gmbh & Co Kg | Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb) |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
CA3093888A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
WO2019213584A1 (en) * | 2018-05-03 | 2019-11-07 | Emory University | Modulators of orphan nuclear receptors for nash and other metabolic disorders |
TWI815887B (zh) * | 2018-05-15 | 2023-09-21 | 美商愛彼特生物製藥股份有限公司 | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
AR116948A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
AR116947A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
UY38437A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) |
UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
AR116946A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
WO2020089460A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) |
TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチドおよびそのプロドラッグ |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
BR112021021580A2 (pt) | 2019-04-30 | 2022-01-04 | Aicuris Gmbh & Co Kg | Fenil e piridil ureias inovadoras ativas contra o vírus da hepatite b (hbv) |
EP3962914A1 (en) | 2019-04-30 | 2022-03-09 | AiCuris GmbH & Co. KG | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
CA3138380A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
AU2020265392A1 (en) | 2019-04-30 | 2021-12-23 | Aicuris Gmbh & Co. Kg | Novel indolizine-2-carboxamides active against the hepatitis B virus (HBV) |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
SG11202112590WA (en) * | 2019-05-24 | 2021-12-30 | Assembly Biosciences Inc | Pharmaceutical compositions for the treatment of hbv |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
JP2023502675A (ja) * | 2019-11-22 | 2023-01-25 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 核タンパク質阻害剤の結晶形及びその使用 |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
AU2021236130A1 (en) * | 2020-03-11 | 2022-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
TW202200161A (zh) | 2020-03-20 | 2022-01-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
AR121905A1 (es) * | 2020-04-22 | 2022-07-20 | Assembly Biosciences Inc | Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv |
CN113929648A (zh) * | 2020-07-14 | 2022-01-14 | 浙江晖石药业有限公司 | 一种环丁烷-1,2-二甲酸酐及其中间体的制备方法 |
CN116194144A (zh) | 2020-08-07 | 2023-05-30 | 吉利德科学公司 | 膦酰胺核苷酸类似物的前药及其药物用途 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | TLR8調節化合物と抗HBV siRNA治療薬との組合せ |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US688762A (en) * | 1901-06-19 | 1901-12-10 | Charles Weber | Toy. |
GB1480553A (en) | 1976-06-03 | 1977-07-20 | Pfizer Ltd | Tricyclic sulphonamides |
JPS58225074A (ja) | 1982-06-25 | 1983-12-27 | Chugai Pharmaceut Co Ltd | ジベンゾオキサゼピン誘導体 |
GB9109557D0 (en) | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
DE19624659A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
DE102004004928A1 (de) | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
US20070105819A1 (en) | 2005-10-17 | 2007-05-10 | Roger Olsson | CB-1 modulating compounds and their use |
US20070105835A1 (en) * | 2005-11-07 | 2007-05-10 | Kazantsev Aleksey G | Compositions and methods for modulating poly(ADP-ribose) polymerase activity |
JP4042065B1 (ja) | 2006-03-10 | 2008-02-06 | 健治 吉田 | 情報処理装置への入力処理システム |
WO2008036139A2 (en) | 2006-06-07 | 2008-03-27 | The Regents Of The University Of California | Inhibitors of mshc and homologs thereof, and methods of identifying same |
WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
EP2313100B1 (en) | 2008-07-23 | 2016-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the plasmodial surface anion channel as antimalarials |
EP2376495A4 (en) * | 2008-12-08 | 2012-10-31 | Vm Pharma Llc | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS |
CN104530079B (zh) * | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
WO2012045194A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
US9399619B2 (en) * | 2011-07-01 | 2016-07-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection |
US9968650B2 (en) | 2011-07-13 | 2018-05-15 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
CN104302626B (zh) | 2012-01-06 | 2016-09-07 | 爱尔兰詹森科学公司 | 4,4-二取代的-1,4-二氢嘧啶及其作为治疗乙型肝炎的药物的用途 |
DK2890683T3 (en) | 2012-08-28 | 2017-01-30 | Janssen Sciences Ireland Uc | MERGED BICYCLIC SULFAMOYL DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
NZ704752A (en) | 2012-08-28 | 2018-06-29 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
CN105051017A (zh) | 2012-11-09 | 2015-11-11 | 美国印第安纳大学研究和技术公司 | 用于hbv组装效应剂的替代用途 |
SG10201900695PA (en) | 2012-12-06 | 2019-02-27 | Baruch S Blumberg Inst | Functionalized benzamide derivatives as antiviral agents against hbv infection |
WO2014106019A2 (en) | 2012-12-27 | 2014-07-03 | Philadelphia Health & Education Corporation, D/B/A Drexel | Novel antiviral agents against hbv infection |
RU2519546C1 (ru) | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
CA2907243C (en) | 2013-03-15 | 2021-12-28 | Celgene Avilomics Research, Inc. | Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor |
ES2640063T3 (es) | 2013-04-03 | 2017-10-31 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B |
EP2997032B1 (en) | 2013-05-17 | 2018-07-25 | F.Hoffmann-La Roche Ag | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
MX366787B (es) | 2013-05-17 | 2019-07-23 | Janssen Sciences Ireland Uc | Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b. |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
MX2015017655A (es) | 2013-06-19 | 2016-04-15 | Seragon Pharmaceuticals Inc | Modulador de receptores de estrogeno y uso del mismo. |
WO2015017412A1 (en) * | 2013-07-29 | 2015-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists |
CA2942533C (en) * | 2014-03-13 | 2020-12-08 | Indiana University Research And Technology Corporation | Hepatitis b core protein allosteric modulators |
PL3154949T3 (pl) | 2014-06-10 | 2018-08-31 | Basf Se | PODSTAWIONE ZWIĄZKI [1,2,4]TRIAZOLOWE i IMIDAZOLOWE JAKO FUNGICYDY |
TWI786639B (zh) | 2015-09-15 | 2022-12-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
-
2016
- 2016-09-14 TW TW110118046A patent/TWI786639B/zh active
- 2016-09-14 TW TW105130074A patent/TWI721016B/zh not_active IP Right Cessation
- 2016-09-14 TW TW105130078A patent/TWI730985B/zh active
- 2016-09-14 TW TW105130076A patent/TW201720802A/zh unknown
- 2016-09-15 CN CN201680065137.2A patent/CN108348529A/zh active Pending
- 2016-09-15 CN CN202010540566.9A patent/CN112094264A/zh active Pending
- 2016-09-15 AU AU2016323305A patent/AU2016323305A1/en not_active Abandoned
- 2016-09-15 US US15/760,284 patent/US10377748B2/en active Active
- 2016-09-15 EA EA201890736A patent/EA201890736A1/ru unknown
- 2016-09-15 AR ARP160102819A patent/AR106040A1/es unknown
- 2016-09-15 DK DK16847295.9T patent/DK3349580T3/da active
- 2016-09-15 AR ARP160102820A patent/AR106041A1/es unknown
- 2016-09-15 US US15/760,387 patent/US10766890B2/en active Active
- 2016-09-15 SG SG10202011103UA patent/SG10202011103UA/en unknown
- 2016-09-15 EP EP16847298.3A patent/EP3349761B1/en active Active
- 2016-09-15 CA CA2998793A patent/CA2998793A1/en not_active Abandoned
- 2016-09-15 AU AU2016323297A patent/AU2016323297A1/en not_active Abandoned
- 2016-09-15 KR KR1020187010455A patent/KR20180053363A/ko not_active Application Discontinuation
- 2016-09-15 MX MX2018003207A patent/MX2018003207A/es unknown
- 2016-09-15 WO PCT/US2016/051934 patent/WO2017048950A1/en active Application Filing
- 2016-09-15 EP EP16847295.9A patent/EP3349580B1/en active Active
- 2016-09-15 LT LTEP16847295.9T patent/LT3349580T/lt unknown
- 2016-09-15 WO PCT/US2016/051949 patent/WO2017048962A1/en active Application Filing
- 2016-09-15 US US15/760,343 patent/US10392379B2/en not_active Expired - Fee Related
- 2016-09-15 KR KR1020187010461A patent/KR20180050405A/ko unknown
- 2016-09-15 KR KR1020187010462A patent/KR20180050406A/ko unknown
- 2016-09-15 EP EP20185808.1A patent/EP3782626A1/en active Pending
- 2016-09-15 CA CA2998741A patent/CA2998741C/en active Active
- 2016-09-15 JP JP2018513782A patent/JP7023838B2/ja active Active
- 2016-09-15 EA EA201890735A patent/EA201890735A1/ru unknown
- 2016-09-15 EA EA201890731A patent/EA201890731A1/ru unknown
- 2016-09-15 ES ES16847305T patent/ES2905950T3/es active Active
- 2016-09-15 WO PCT/US2016/051940 patent/WO2017048954A1/en active Application Filing
- 2016-09-15 SI SI201630982T patent/SI3349580T1/sl unknown
- 2016-09-15 ES ES16847295T patent/ES2831333T3/es active Active
- 2016-09-15 EP EP16847305.6A patent/EP3349581B8/en active Active
- 2016-09-15 CN CN201680065139.1A patent/CN108347942B/zh not_active Expired - Fee Related
- 2016-09-15 CA CA2998803A patent/CA2998803A1/en not_active Abandoned
- 2016-09-15 MX MX2018003206A patent/MX2018003206A/es unknown
- 2016-09-15 PT PT168472959T patent/PT3349580T/pt unknown
- 2016-09-15 JP JP2018513837A patent/JP2018531921A/ja active Pending
- 2016-09-15 CN CN201680065785.8A patent/CN108347943B/zh active Active
- 2016-09-15 RS RS20201384A patent/RS61064B1/sr unknown
- 2016-09-15 AU AU2016323293A patent/AU2016323293B2/en active Active
- 2016-09-15 AR ARP160102816A patent/AR106037A1/es unknown
- 2016-09-15 HU HUE16847295A patent/HUE051872T2/hu unknown
- 2016-09-15 MX MX2018003198A patent/MX2018003198A/es unknown
- 2016-09-15 JP JP2018513789A patent/JP2018531919A/ja active Pending
-
2018
- 2018-03-13 IL IL258099A patent/IL258099A/en unknown
- 2018-03-13 IL IL258097A patent/IL258097A/en unknown
- 2018-03-14 MX MX2022005899A patent/MX2022005899A/es unknown
- 2018-03-14 IL IL258124A patent/IL258124B/en active IP Right Grant
- 2018-03-15 PH PH12018500572A patent/PH12018500572A1/en unknown
- 2018-03-15 DO DO2018000074A patent/DOP2018000074A/es unknown
- 2018-03-15 PH PH12018500573A patent/PH12018500573A1/en unknown
- 2018-03-15 PH PH12018500571A patent/PH12018500571A1/en unknown
- 2018-03-15 CL CL2018000684A patent/CL2018000684A1/es unknown
- 2018-04-13 ZA ZA2018/02456A patent/ZA201802456B/en unknown
-
2019
- 2019-01-22 HK HK19101079.1A patent/HK1258761A1/zh unknown
- 2019-01-22 HK HK19101078.2A patent/HK1258697A1/zh unknown
- 2019-01-22 HK HK19101106.8A patent/HK1259141A1/zh unknown
- 2019-05-28 CL CL2019001433A patent/CL2019001433A1/es unknown
- 2019-05-30 US US16/426,727 patent/US10968211B2/en active Active
-
2020
- 2020-11-13 HR HRP20201812TT patent/HRP20201812T1/hr unknown
- 2020-11-16 CY CY20201101088T patent/CY1123570T1/el unknown
-
2021
- 2021-01-04 US US17/140,800 patent/US11814376B2/en active Active
- 2021-01-18 JP JP2021005706A patent/JP7150903B2/ja active Active
- 2021-04-01 AU AU2021202065A patent/AU2021202065B2/en active Active
-
2023
- 2023-09-01 US US18/460,337 patent/US20240025890A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258761A1 (zh) | 乙肝核心蛋白調節劑 | |
IL282391A (en) | Allosteric modulators of hepatitis B core protein | |
HK1244019A1 (zh) | 融合蛋白 | |
GB201515745D0 (en) | Proteins | |
GB201511787D0 (en) | Proteins | |
GB201504691D0 (en) | Fusion protein | |
GB201513033D0 (en) | Proteins | |
GB201515744D0 (en) | Proteins | |
GB201503778D0 (en) | Proteins | |
GB201509671D0 (en) | Web-winding core |